{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:51:07Z","timestamp":1777657867128,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341213"],"award-info":[{"award-number":["82341213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2023-I2M-C&T-B-105"],"award-info":[{"award-number":["2023-I2M-C&T-B-105"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2024-I2M-ZH-015"],"award-info":[{"award-number":["2024-I2M-ZH-015"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06827-2","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:18:05Z","timestamp":1753726685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel loop structure of human IgG1 Fc fused CD38 targeted bispecific antibodies and their anti-tumor effect in acute myeloid leukemia"],"prefix":"10.1186","volume":"23","author":[{"given":"Shisen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifeng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaowei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runxia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-9151","authenticated-orcid":false,"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"6827_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf Daniel J, Bloomfield Clara D. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"6827_CR2","first-page":"46","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, Jabbour E, Schiffer CA, Lang A, Ravandi F. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025;75:46\u201367.","journal-title":"CA Cancer J Clin"},{"key":"6827_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","volume":"16","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023;16:22.","journal-title":"J Hematol Oncol"},{"key":"6827_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/2643-3230.BCD-23-0202","volume":"5","author":"C Restelli","year":"2024","unstructured":"Restelli C, Ruella M, Paruzzo L, Tarella C, Pelicci PG, Colombo E. Recent advances in immune-based therapies for acute myeloid leukemia. Blood Cancer Discov. 2024;5:234\u201348.","journal-title":"Blood Cancer Discov"},{"key":"6827_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet (London, England). 2021;397:410\u201327.","journal-title":"Lancet (London, England)"},{"key":"6827_CR6","doi-asserted-by":"publisher","first-page":"22062","DOI":"10.1038\/s41598-021-01300-8","volume":"11","author":"M Farber","year":"2021","unstructured":"Farber M, Chen Y, Arnold L, M\u00f6llmann M, Boog-Whiteside E, Lin Y-A, Reinhardt HC, D\u00fchrsen U, Hanoun M. Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis. Sci Rep. 2021;11:22062.","journal-title":"Sci Rep"},{"key":"6827_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","volume":"14","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, Hilder B, Tolbert J, Renaud T, Masterson T, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024;14:24.","journal-title":"Blood Cancer J"},{"key":"6827_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.molmed.2008.02.005","volume":"14","author":"S Deaglio","year":"2008","unstructured":"Deaglio S, Aydin S, Vaisitti T, Bergui L, Malavasi F. CD38 at the junction between prognostic marker and therapeutic target. Trends Mol Med. 2008;14:210\u20138.","journal-title":"Trends Mol Med"},{"key":"6827_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13:125.","journal-title":"J Hematol Oncol"},{"key":"6827_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discovery. 2019;18:585\u2013608.","journal-title":"Nat Rev Drug Discovery"},{"key":"6827_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","volume":"32","author":"A Thakur","year":"2018","unstructured":"Thakur A, Huang M, Lum LG. Bispecific antibody based therapeutics: strengths and challenges. Blood Rev. 2018;32:339\u201347.","journal-title":"Blood Rev"},{"key":"6827_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","volume":"24","author":"F Galvez-Cancino","year":"2024","unstructured":"Galvez-Cancino F, Simpson AP, Costoya C, Matos I, Qian D, Peggs KS, Litchfield K, Quezada SA. Fc\u03b3 receptors and immunomodulatory antibodies in cancer. Nat Rev Cancer. 2024;24:51\u201371.","journal-title":"Nat Rev Cancer"},{"key":"6827_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40164-023-00423-0","volume":"12","author":"M Chen","year":"2023","unstructured":"Chen M, Liu X, Peng N, Zhang T, Mou J, He H, Wang Y, Xu Y, Xing H, Tang K, et al. Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy. Exp Hematol Oncol. 2023;12:64.","journal-title":"Exp Hematol Oncol"},{"key":"6827_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-022-2173-9","author":"Z Chen","year":"2022","unstructured":"Chen Z, Liu Y, Chen N, Xing H, Tian Z, Tang K, Rao Q, Xu Y, Wang Y, Wang M, Wang J. Loop CD20\/CD19 CAR-T cells eradicate B-cell malignancies efficiently. Sci China Life Sci. 2022. https:\/\/doi.org\/10.1007\/s11427-022-2173-9.","journal-title":"Sci China Life Sci"},{"key":"6827_CR15","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/bloodadvances.2024014182","volume":"9","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lv L, Song Y, Wei X, Zhou H, Liu Q, Xu K, Yan D, Zhang C, Liu S, et al. Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2025;9:836\u201343.","journal-title":"Blood Adv"},{"key":"6827_CR16","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/bloodadvances.2024013212","volume":"8","author":"E Mart\u00edn-S\u00e1nchez","year":"2024","unstructured":"Mart\u00edn-S\u00e1nchez E, Blanco L, Kim PS, Bisht K, Wang H, Van de Velde H, Jelinek T, Simoes C, Prosper F, San Miguel JF, et al. Targeting CD38 with isatuximab and a novel CD38\/CD3\u00d7CD28 trispecific T-cell engager in older patients with acute myeloid leukemia. Blood Adv. 2024;8:3875\u20139.","journal-title":"Blood Adv"},{"key":"6827_CR17","first-page":"127.e121","volume":"29","author":"M Klimentova","year":"2023","unstructured":"Klimentova M, Shelikhova L, Ilushina M, Kozlovskaya S, Blagov S, Popov A, Kashpor S, Fadeeva M, Olshanskaya J, Glushkova S, et al. Targeted therapy with venetoclax and daratumumab as part of HSCT preparative regimen in children with chemorefractory acute myeloid leukemia. Transplant Cell Ther. 2023;29:127.e121-127.e129.","journal-title":"Transplant Cell Ther"},{"key":"6827_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-021-00291-y","volume":"9","author":"JJ Mistry","year":"2021","unstructured":"Mistry JJ, Hellmich C, Lambert A, Moore JA, Jibril A, Collins A, Bowles KM, Rushworth SA. Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia. Biomarker Res. 2021;9:35.","journal-title":"Biomarker Res"},{"key":"6827_CR19","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver N, Alotaibi AS, B\u00fccklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35:1843\u201363.","journal-title":"Leukemia"},{"key":"6827_CR20","doi-asserted-by":"publisher","first-page":"S460","DOI":"10.1067\/mai.2003.108","volume":"111","author":"LC Borish","year":"2003","unstructured":"Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol. 2003;111:S460\u201375.","journal-title":"J Allergy Clin Immunol"},{"key":"6827_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","volume":"16","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo A, \u00c1lvarez-Vallina L, Sanz L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023;16:83.","journal-title":"J Hematol Oncol"},{"key":"6827_CR22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2023-174563","volume":"142","author":"B Pouleau","year":"2023","unstructured":"Pouleau B, Estoppey C, Suere P, Nallet E, Laurendon A, Monney T, Pais Ferreira D, Drake A, Carretero-Iglesia L, Macoin J, et al. Preclinical characterization of ISB 1342, a CD38 \u00d7 CD3 T-cell engager for relapsed\/refractory multiple myeloma. Blood. 2023;142:260\u201373.","journal-title":"Blood"},{"key":"6827_CR23","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","volume":"25","author":"CL Zuch de Zafra","year":"2019","unstructured":"Zuch de Zafra CL, Fajardo F, Zhong W, Bernett MJ, Muchhal US, Moore GL, Stevens J, Case R, Pearson JT, Liu S, et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin Cancer Res. 2019;25:3921\u201333.","journal-title":"Clin Cancer Res"},{"key":"6827_CR24","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","volume":"390","author":"Y Chen","year":"2024","unstructured":"Chen Y, Xu Y, Li H, Sun T, Cao X, Wang Y, Xue F, Liu W, Liu X, Dong H, et al. A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia. N Engl J Med. 2024;390:2178\u201390.","journal-title":"N Engl J Med"},{"key":"6827_CR25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf L, Burns M, Durek P, Heinz Gitta A, Heinrich F, Garantziotis P, Enghard P, Richter U, Biesen R, Schneider U, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383:1149\u201355.","journal-title":"N Engl J Med"},{"key":"6827_CR26","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s43587-024-00670-8","volume":"4","author":"Z Song","year":"2024","unstructured":"Song Z, Park SH, Mu W-C, Feng Y, Wang C-L, Wang Y, Barthez M, Maruichi A, Guo J, Yang F, et al. An NAD+-dependent metabolic checkpoint regulates hematopoietic stem cell activation and aging. Nature Aging. 2024;4:1384\u201393.","journal-title":"Nature Aging"},{"key":"6827_CR27","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","volume":"8","author":"L Chen","year":"2018","unstructured":"Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade. Cancer Discov. 2018;8:1156\u201375.","journal-title":"Cancer Discov"},{"key":"6827_CR28","doi-asserted-by":"publisher","first-page":"e2315989121","DOI":"10.1073\/pnas.2315989121","volume":"121","author":"A Kar","year":"2024","unstructured":"Kar A, Ghosh P, Gautam A, Chowdhury S, Basak D, Sarkar I, Bhoumik A, Barman S, Chakraborty P, Mukhopadhyay A, et al. CD38-RyR2 axis-mediated signaling impedes CD8+ T cell response to anti-PD1 therapy in cancer. Proc Natl Acad Sci USA. 2024;121:e2315989121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6827_CR29","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3390\/cells9071716","volume":"9","author":"A Kar","year":"2020","unstructured":"Kar A, Mehrotra S, Chatterjee S. CD38: T cell immuno-metabolic modulator. Cells. 2020;9:1716.","journal-title":"Cells"},{"key":"6827_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S1074-7613(00)80353-2","volume":"7","author":"G Shubinsky","year":"1997","unstructured":"Shubinsky G, Schlesinger M. The CD38 lymphocyte differentiation marker: new insight into its ectoenzymatic activity and its role as a signal transducer. Immunity. 1997;7:315\u201324.","journal-title":"Immunity"},{"key":"6827_CR31","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1182\/blood.2024027500","volume":"145","author":"R Bassan","year":"2025","unstructured":"Bassan R, Chiaretti S, Della Starza I, Santoro A, Spinelli O, Tosi M, Elia L, Cardinali D, De Propris MS, Piccini M, et al. Up-front blinatumomab improves MRD clearance and outcome in adult Ph\u2013 B-lineage ALL: the GIMEMA LAL2317 phase 2 study. Blood. 2025;145:2447\u201359.","journal-title":"Blood"},{"key":"6827_CR32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.287119","author":"B Gong","year":"2025","unstructured":"Gong B, Yang M, Qiu S, Liu B, Wang Y, Mi Y, Wei H, Wang J. Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia. Haematologica. 2025. https:\/\/doi.org\/10.3324\/haematol.2024.287119.","journal-title":"Haematologica"},{"key":"6827_CR33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12943-016-0574-7","volume":"16","author":"X Wang","year":"2017","unstructured":"Wang X, Huang S, Chen J-L. Understanding of leukemic stem cells and their clinical implications. Mol Cancer. 2017;16:2.","journal-title":"Mol Cancer"},{"key":"6827_CR34","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood.2023021570","volume":"143","author":"M Murtadha","year":"2024","unstructured":"Murtadha M, Park M, Zhu Y, Caserta E, Napolitano O, Tandoh T, Moloudizargari M, Pozhitkov A, Singer M, Dona AA, et al. A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-\u03b3-induced CD38 expression. Blood. 2024;143:1599\u2013615.","journal-title":"Blood"},{"key":"6827_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","volume":"136","author":"D Nagorsen","year":"2012","unstructured":"Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136:334\u201342.","journal-title":"Pharmacol Ther"},{"key":"6827_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","volume":"29","author":"WR Strohl","year":"2015","unstructured":"Strohl WR. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs. 2015;29:215\u201339.","journal-title":"BioDrugs"},{"key":"6827_CR37","doi-asserted-by":"crossref","unstructured":"Plenary abstracts session & oral presentations. HemaSphere. 2025;9:e70151. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70151","DOI":"10.1002\/hem3.70151"},{"key":"6827_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","volume":"1","author":"L Wu","year":"2020","unstructured":"Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, Cortez-Retamozo V, Ospina B, Posternak V, Ulinski G, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer. 2020;1:86\u201398.","journal-title":"Nat Cancer"},{"key":"6827_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/protein\/gzw040","volume":"29","author":"T Schlothauer","year":"2016","unstructured":"Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Uma\u00f1a P, M\u00f6ssner E. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel PEDS. 2016;29:457\u201366.","journal-title":"Protein Eng Des Sel PEDS"},{"key":"6827_CR40","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jaci.2020.09.016","volume":"146","author":"SW Canna","year":"2020","unstructured":"Canna SW, Cron RQ. Highways to hell: mechanism-based management of cytokine storm syndromes. J Allergy Clin Immunol. 2020;146:949\u201359.","journal-title":"J Allergy Clin Immunol"},{"key":"6827_CR41","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"M-E Goebeler","year":"2020","unstructured":"Goebeler M-E, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020;17:418\u201334.","journal-title":"Nat Rev Clin Oncol"},{"key":"6827_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.tips.2022.12.005","volume":"44","author":"J Kim","year":"2023","unstructured":"Kim J, McFee M, Fang Q, Abdin O, Kim PM. Computational and artificial intelligence-based methods for antibody development. Trends Pharmacol Sci. 2023;44:175\u201389.","journal-title":"Trends Pharmacol Sci"},{"key":"6827_CR43","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, Wang SA, Bagg A, Barbui T, Branford S, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"6827_CR44","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06827-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06827-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06827-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:51:59Z","timestamp":1757310719000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06827-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6827"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06827-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study of patients and animal experiments was approved by the Ethics Review Board of IHCAMS. All patients and health donors were informed, and written consents were signed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"849"}}